Prof. Dr. Xiao-qian Chen, Huazhong University of Science and Technology, China.
Prof. Xiao Qian Chen 🧠 is a leading neurobiology and oncology researcher with over 25 high-impact publications 📚. As a Principal Investigator on 10+ national grants, he has pioneered studies on glioblastoma and neuroglobin. A professor since 2007, he’s received multiple awards 🏅 and holds a patent for neural therapy innovation. His international collaborations 🌍 and mentorship of young scientists 👨🔬 make him a driving force in translational brain research.
Profile
Scopus Profile
Orcid Profile
🎓 Early Academic Pursuits
Prof. Dr. Xiao Qian Chen embarked on his academic journey with a Bachelor of Medicine from Shanghai Medical University in 1988. He then pursued a Master’s in Medicine specializing in immunology at Peking Union Medical College and the Chinese Academy of Medical Sciences, graduating in 1997, followed by a Ph.D. in Biology from The Hong Kong University of Science and Technology in 2002. His foundational studies equipped him with a robust interdisciplinary grounding in medicine, immunology, and cutting-edge biological research. 🏛️
💼 Professional Endeavors
Following his Ph.D., Xiao Qian Chen served as an Engineer (1997–1999) at the Laboratory of Molecular Virology, CAS, Beijing. He transitioned to clinical work as a Surgeon (1988–1994) at Xi-Yuan Hospital, blending research with hands-on patient care. His postdoctoral stints included work at Peking University Neuroscience Research Institute (2002–2004) and as a Postdoc/Visiting Scholar (2010–2011) at Emory University’s Pharmacology Department. In academia, he rose from Associate Professor (2004–2007) to Professor from November 2007 at the Department of Pathophysiology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan—where he continues to lead cutting-edge research.
🔬 Contributions and Research Focus On Pharmacology
Prof. Chen’s research centers on neuroglobin biology, glioblastoma immunology, and neuronal survival under stress. As principal investigator, he has led over ten major projects funded by the National Natural Science Foundation of China, exploring mechanisms of glioma cytotoxicity, astrocyte transformation, and neuroprotection through signaling pathways (e.g., EGFR/PTEN/AKT/PD‑L1). Key themes include neuroglobin’s dual role in oxygen sensing and neuroprotection, and the therapeutic targeting of PD‑L1 and metabolic pathways in brain tumors.
🌍 Impact and Influence
Prof. Chen’s body of work has advanced understanding in both neurobiology and cancer biology. He has identified novel molecular targets such as neuroglobin and PD‑L1, elucidating their roles from neurite outgrowth and hypoxia responses to tumor immunity and chemoradiotherapy resistance. His integrative approach blends molecular experiments, in vivo models, and therapeutic studies, influencing subsequent research in glioblastoma treatment and neuroprotective strategies.
🧠 Research Skills
Prof. Chen’s methodology toolbox is robust and diverse:
-
Cell and molecular biology (protein interactions, gene expression)
-
Animal models (glioblastoma, ischemic stroke, autism, depression)
-
Neurochemistry & signaling assays (EGFR/PTEN/AKT, p38/JNK, autophagy pathways)
-
Immunology techniques (PD‑L1/PD‑1, microglia phenotyping, T‑cell infiltration)
-
Translational therapeutics, especially pharmacological modulation (e.g., Piperlongumine, CD73 inhibitors)
🏅 Awards and Honors
Prof. Chen’s excellence has been recognized through prestigious awards:
-
Second Prize, China Medical Science & Technology Award (2006) — for protective mechanisms in astrocytes during cerebral ischemia.
-
Second Prize, Hubei Science & Technology Progress Award (2019) — for work on Piperlongumamide in cancer treatment.
These accolades affirm the scientific and societal relevance of his discoveries.
🏛️ Legacy and Future Contributions
Prof. Chen’s enduring legacy lies in his cross-disciplinary integration of neuroscience and oncology, particularly in harnessing metabolic and immune modulation for disease intervention. Going forward, his ongoing grants (2022–2025) position him to lead breakthroughs in microglia reprogramming, astrocyte plasticity, and glioblastoma therapeutics. The translational promise of his research holds potential for neuroprotective and immunomodulatory therapies in serious CNS disorders.
Publications Top Notes
-
📘 Acta Pharmacologica Sinica (2025)
Title: CD73 inhibitor AB680 suppresses glioblastoma in mice…
📅 Year: 2025
-
🧠 Theranostics (2025)
Title: A molecularly distinct cell type in the midbrain regulates intermale aggression…
📅 Year: 2025
-
🧬 Journal of Experimental & Clinical Cancer Research (2023)
Title: Piperlongumine conquers temozolomide chemoradiotherapy resistance…
📅 Year: 2023
-
🧠 Neuroscience Bulletin (2023)
Title: Neuroglobin Facilitates Neuronal Oxygenation through Tropic Migration…
📅 Year: 2023
-
🧩 Molecular Neurobiology (2023)
Title: KMT2E Haploinsufficiency Manifests Autism-Like Behaviors…
📅 Year: 2023
-
🔬 Biochemical and Biophysical Research Communications (2021)
Title: Rapid tumor recurrence in a novel murine GBM surgical model…
📅 Year: 2021
-
🧪 Clinical and Translational Medicine (2020)
Title: Mannose synergizes with chemoradiotherapy to cure cancer…
📅 Year: 2020
-
🧠 Frontiers in Oncology (2019)
Title: The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion…
📅 Year: 2019
-
📡 Nature Communications (2019)
Title: Locus coeruleus-CA1 projections are involved in chronic-depressive stress…
📅 Year: 2019
-
🧫 Neurochemical Research (2019)
Title: Selective 14-3-3γ Upregulation Promotes Beclin-1-LC3-Autophagic Influx…
📅 Year: 2019
-
💊 Frontiers in Pharmacology (2019)
Title: The prognostic and therapeutic value of PD-L1 in glioma
📅 Year: 2019
-
🧬 Biochimica et Biophysica Acta – Molecular Basis of Disease (2018)
Title: PD-L1 confers glioblastoma multiforme malignancy via Ras binding…
📅 Year: 2018
-
🧠 Cell Death & Disease (2018)
Title: Neuroglobin boosts axon regeneration during ischemic reperfusion…
📅 Year: 2018